Itziar Oyagüez

1.5k total citations
107 papers, 1.1k citations indexed

About

Itziar Oyagüez is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Itziar Oyagüez has authored 107 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Economics and Econometrics. Recurrent topics in Itziar Oyagüez's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Hepatitis C virus research (10 papers) and Hepatitis B Virus Studies (9 papers). Itziar Oyagüez is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Hepatitis C virus research (10 papers) and Hepatitis B Virus Studies (9 papers). Itziar Oyagüez collaborates with scholars based in Spain, United States and Chile. Itziar Oyagüez's co-authors include Miguel Á. Casado, Miguel Casado, Ángel Gil de Miguel, Pilar Carrasco‐Garrido, Antonio González, José Ramón González‐Juanatey, Virginia Becerra, Javier Soto, José María Lobos and Joan Carles Reverter and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Journal of Hepatology.

In The Last Decade

Itziar Oyagüez

102 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Itziar Oyagüez Spain 18 365 185 166 135 128 107 1.1k
Carlo Lucioni Italy 16 361 1.0× 96 0.5× 243 1.5× 74 0.5× 77 0.6× 76 1.1k
Lisa J. McGarry United States 19 681 1.9× 126 0.7× 66 0.4× 153 1.1× 232 1.8× 70 1.5k
B. Ehlken Germany 21 182 0.5× 282 1.5× 114 0.7× 222 1.6× 124 1.0× 53 1.2k
Hui‐Kim Yap Singapore 26 294 0.8× 149 0.8× 25 0.2× 341 2.5× 41 0.3× 141 2.3k
Ross B. Isaacs United States 17 184 0.5× 89 0.5× 54 0.3× 417 3.1× 158 1.2× 28 1.1k
Sara Belga Canada 12 124 0.3× 65 0.4× 79 0.5× 116 0.9× 36 0.3× 35 602
Dahlia Weitzman Israel 20 270 0.7× 139 0.8× 68 0.4× 85 0.6× 24 0.2× 37 1.2k
Alexander Kuhlmann Germany 16 188 0.5× 87 0.5× 74 0.4× 91 0.7× 13 0.1× 47 910
Chikao Yamazaki Japan 18 663 1.8× 115 0.6× 37 0.2× 107 0.8× 810 6.3× 44 1.5k
Frank I. Scott United States 24 523 1.4× 35 0.2× 85 0.5× 547 4.1× 64 0.5× 118 1.8k

Countries citing papers authored by Itziar Oyagüez

Since Specialization
Citations

This map shows the geographic impact of Itziar Oyagüez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Itziar Oyagüez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Itziar Oyagüez more than expected).

Fields of papers citing papers by Itziar Oyagüez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Itziar Oyagüez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Itziar Oyagüez. The network helps show where Itziar Oyagüez may publish in the future.

Co-authorship network of co-authors of Itziar Oyagüez

This figure shows the co-authorship network connecting the top 25 collaborators of Itziar Oyagüez. A scholar is included among the top collaborators of Itziar Oyagüez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Itziar Oyagüez. Itziar Oyagüez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bustamante, Marco, et al.. (2025). Cost-effectiveness analysis of artificial intelligence-aided colonoscopy for adenoma detection and characterization in Spain. Endoscopy International Open. 13(CP). a25097278–a25097278. 1 indexed citations
3.
López-Mínguez, José Ramón, Ángel L.M. de Francisco, María José Soler, et al.. (2023). Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain. Catheterization and Cardiovascular Interventions. 102(2). 233–240. 1 indexed citations
4.
5.
Torres, Esperanza, et al.. (2023). Cost-consequence analysis of penile prosthesis implantation in outpatient setting in Spain. International Journal of Healthcare Management. 17(1). 160–167. 1 indexed citations
6.
Oyagüez, Itziar, Fernando Gómez‐Peralta, Sara Artola, et al.. (2021). Correction to: Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population. Diabetes Therapy. 12(8). 2263–2264. 1 indexed citations
7.
Alsina, Laia, José Bruno Montoro Ronsano, Pedro Moral, et al.. (2021). Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. The European Journal of Health Economics. 23(3). 551–558. 11 indexed citations
8.
Mingot‐Castellano, María Eva, et al.. (2020). Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. European Journal Of Haematology. 105(1). 94–100. 1 indexed citations
9.
Pérez-Ruiz, Fernando, et al.. (2019). Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clinical Rheumatology. 38(12). 3521–3528. 6 indexed citations
10.
Capel, Margarita, et al.. (2018). Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clinical Drug Investigation. 38(7). 611–620. 8 indexed citations
11.
Buti, Marı́a, Raquel Domínguez‐Hernández, Itziar Oyagüez, & Miguel Casado. (2016). Cost–effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis. Gastroenterología y Hepatología (English Edition). 39(7). 449–457. 6 indexed citations
12.
13.
Cueva, P. de la, et al.. (2015). Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain. Value in Health. 18(7). A423–A423. 2 indexed citations
14.
15.
Vanaclocha, F., et al.. (2015). Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain. Value in Health. 18(7). A420–A420. 3 indexed citations
16.
Buti, Marı́a, Itziar Oyagüez, Raúl J. Andrade, et al.. (2014). [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].. SHILAP Revista de lepidopterología. 38(5). 418–29. 9 indexed citations
17.
Menéndez, Rosario, et al.. (2013). Cost-Effectiveness of a 13-Valent Conjugate Pneumococcal Vaccination Program in COPD Patients Aged ≥50 Years in Spain: Preliminary Results. Value in Health. 16(7). A353–A353. 1 indexed citations
18.
Moróte, Juan, J.M. Cózar, Ignacio Durán, et al.. (2013). Cost Assessment of Metastatic and Non-Metastatic Castration-Resistant Prostate Cancer Patient-Management in Spain. Value in Health. 16(7). A405–A405. 1 indexed citations
19.
Miguel, Ángel Gil de, et al.. (2006). Hospitalization by Pneumonia and Influenza in the 50-64 Year Old Population in Spain (1999-2002). Human Vaccines. 2(4). 181–184. 9 indexed citations
20.
Miguel, Ángel Gil de, Itziar Oyagüez, Pilar Carrasco‐Garrido, & Antonio López González. (2001). Epidemiology of primary varicella hospitalizations in Spain. Vaccine. 20(3-4). 295–298. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo Lucioni Breakdown of academic impact, for papers by Lisa J. McGarry Breakdown of academic impact, for papers by B. Ehlken Breakdown of academic impact, for papers by Hui‐Kim Yap Breakdown of academic impact, for papers by Ross B. Isaacs Breakdown of academic impact, for papers by Sara Belga Breakdown of academic impact, for papers by Dahlia Weitzman Breakdown of academic impact, for papers by Alexander Kuhlmann Breakdown of academic impact, for papers by Chikao Yamazaki Breakdown of academic impact, for papers by Frank I. Scott
Rankless by CCL
2026